Patient tailored anti-tumour T cells to prevent relapse in patients with acute myeloid leukaemia undergoing allogeneic haemopoietic stem cell transplantation
Patient tailored anti-tumour T cells to prevent relapse in patients with acute myeloid leukaemia undergoing allogeneic haemopoietic stem cell transplantation
为患者量身定制抗肿瘤T细胞，以预防接受同种异体造血干细胞移植的急性髓系白血病患者复发
批准号：
nhmrc : 1089398
负责人：
Dr Emily Blyth
金额：
$12.7万
依托单位国家：
澳大利亚
项目类别：
Early Career Fellowships
财政年份：
2015
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2015-01-01 至 2018-12-31
中文摘要
翻译
急性髓系白血病(AML)是成人最常见的急性白血病。高危AML患者的两年存活率不到20%。健康捐献者的血液或骨髓移植通常是治愈的唯一机会，但白血病经常复发。Blyth博士将进行一项临床试验，将来自移植捐赠者的抗白血病免疫细胞用于高危AML患者，以防止移植后复发。
英文摘要
Acute myeloid leukaemia (AML) is the most common acute leukaemia in adults. Patients with high-risk AML have a 2-year survival of less than 20%. Blood or bone marrow transplant from a healthy donor is often the only chance of cure but the leukaemia frequently returns. Dr Blyth will perform a clinical trial giving leukaemia fighting immune cells from the transplant donor to patients with high risk AML to prevent relapse after transplant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A trial of tumour antigen targeted donor T cells in high risk acute myeloid leukaemia
-
批准号：nhmrc : GNT1088118
-
项目类别：Project Grants
-
资助金额：$39.13万
-
财政年份：2015
-
负责人：Dr Emily Blyth
-
依托单位：
Patient tailored anti-tumour T cells to prevent relapse in patients with acute myeloid leukaemia undergoing allogeneic haemopoietic stem cell transplantation
-
批准号：nhmrc : GNT1089398
-
项目类别：Early Career Fellowships
-
资助金额：$18.47万
-
财政年份：2015
-
负责人：Dr Emily Blyth
-
依托单位：
A trial of tumour antigen targeted donor T cells in high risk acute myeloid leukaemia
-
批准号：nhmrc : 1088118
-
项目类别：Project Grants
-
资助金额：$26.94万
-
财政年份：2015
-
负责人：Dr Emily Blyth
-
依托单位：
海外基金
